Form 8K PAVmed Inc For: 14 August
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
PAVmed Inc (PAVM)
The PAVmed share price today is 3.960, view NASDAQ PAVM stock exchange data. Track the latest PAVmed share price with real-time updates on PAVM stock performance including market cap, day range, 52-week range and dividend yield. Access PAVM charts, earnings dates and analyst estimates to support your investment decisions.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.880
4.290
52 wk Range
3.700
28.440
PAVM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.8804.290
52 wk Range
3.70028.440
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PAVM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
36.500
Upside
+821.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
May have trouble making interest payments on debt
Form 13G PAVMED INC. For: 11 May- Investing.com
- Form 8K PAVmed Inc For: 14 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 36.500
(+821.72% Upside)
PAVmed Inc Earnings Call Summary for Q2/2026
- PAVmed narrowed Q2 GAAP net loss to $5.5M ($0.87/share) from $12.3M year-ago, aided by lower non-cash fair-value charges on Lucid shares.
- PortIO may pursue faster 510(k) FDA pathway vs. de novo route; pre-submission meeting targeted Q4 2026, potentially reducing time and cost to market.
- Veris enrollment at Ohio State accelerating toward 1,000-patient first-year target; implantable monitor 510(k) submission expected early 2027.
- Cash position stood at $3.8M at June 30 despite $30M preferred stock financing; company burning cash quickly with -228% gross margin.
- Shares fell 2.74% to $4.61, down 83.8% from 52-week high of $28.44, reflecting investor caution over limited cash and continued losses.
Last Updated: 14-08-2026, 07:12 pm
Read Full TranscriptEarnings
Latest Release
13-08-2026
EPS / Forecast
-0.87 / --
Revenue / Forecast
33K / 100K
Compare PAVM to Peers and Sector
Metrics to compare | PAVM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPAVMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −6.6x | −0.4x | |
PEG Ratio | 0.01 | −0.26 | 0.00 | |
Price/Book | 0.9x | 2.3x | 2.6x | |
Price / LTM Sales | 247.2x | 2.3x | 3.0x | |
Upside (Analyst Target) | - | 49.3% | 54.5% | |
Fair Value Upside | Unlock | −6.3% | 7.2% | Unlock |
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the PAVmed (PAVM) Share Price Today?
The PAVmed share price today is 3.960.
What is the current PAVmed (PAVM) share price and day range?
As of 20-09-2026, the PAVmed share price is 3.960, with a previous close of 3.960. The share price has ranged from 3.880 to 4.290 today, while the 52-week range spans from 3.700 to 28.440.
What Is the PAVmed Market Cap?
As of today, PAVmed market cap is 27.760M.
What Is the PAVmed (PAVM) Share Price Target?
The average 12-month share price target for PAVmed is 36.500, with a high estimate of 57 and a low estimate of 16. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +821.72% Upside potential.
What Is PAVmed's Earnings Per Share (TTM)?
The PAVmed EPS (TTM) is -9.852.
From a Technical Analysis Perspective, Is PAVM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does PAVmed Trade On?
PAVmed is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for PAVmed?
The stock symbol for PAVmed is "PAVM."
How Many Times Has PAVmed Stock Split?
PAVmed has split 2 times.
How Many Employees Does PAVmed Have?
PAVmed has 41 employees.
What Is the PAVM Premarket Price?
PAVM's last pre-market stock price is 4.120. The pre-market share volume is 225.000, and the stock has changed by 0.150, or 3.780%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.